Junshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs

Bulletin Express

Mar 12

Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.

The company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.

Management confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.

The board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1179340994"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179340994\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179340994?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179340994","market":"hk","top_or_hot":-1,"title":"Junshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs","media":"Bulletin Express","content":"<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.</p>\n<p>The company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.</p>\n<p>Management confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.</p>\n<p>The board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-12 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.</p>\n<p>The company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.</p>\n<p>Management confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.</p>\n<p>The board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1179340994","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179340994","pubTimestamp":1773315771,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"君实生物(01877)全额返还此前用于营运资金需求的闲置募集资金11.1亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.\nThe company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.\nManagement confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.\nThe board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}